Curcumin, obtained from turmeric, has several biological properties to make it a desirable template for drug development. A lipophilic derivative of curcumin, diacetyl curcumin (DAC) and a hydrophilic derivative, diglutaryl curcumin (DGC) were synthesized and their in vivo analgesic and anti-inflammatory activities were compared with those of curcumin and aspirin. The in vitro anti-cancer activities of curcumin and the two derivatives against three cell cancer lines were compared with those against a non-cancerous cell line. The inhibitory effects were comparable to each other and nearing that of curcumin while they showed low inhibitory effect towards the non-cancerous cell line. The mouse tail flick assay showed that curcumin, DAC and DGC increased latency time. DGC was most effective as an analgesic, even more so than aspirin. The maximum percentage effect (MPE) was highest with DGC at 3 hours. The carrageenan induced paw edema model indicated anti-inflammatory activity of all three curcumin formulations. The percentage inhibition of paw edema was maximum for DAC, followed by aspirin and curcumin.
Turmeric (Curcuma longa) is known as the golden spice and is commonly used as a spice, flavoring and coloring agent. Turmeric extract has shown biological properties including antiinflammatory, antioxidant, anti-carcinogenic, anti-mutagenic, anticoagulant, anti-fertility, anti-diabetic, antibacterial, antifungal, antiprotozoal, antiviral, anti-fibrotic, antivenum, antiulcer, hypotensive, and hypocholesteremic activities [1]. One of the major active ingredients in turmeric is curcumin, [1E,6E)-1,7-bis(4hydroxy-3-methoxyphenyl)hepta-1,6-dione]. One major limitation of curcumin is its poor bioavailability due to lack of water solubility. Curcumin is a relatively polar molecule and therefore is not very lipophilic either. Curcumin's limited therapeutic application is also due to its instability in physiological conditions [2] [3] [4] [5] [6] [7] . Commercial curcumin is a mixture of curcumin (77%), demethoxy curcumin (17%) and bisdemethoxy curcumin (3%). We have chosen curcumin and two curcumin derivatives, di-acetyl curcumin (DAC) [8] and di-glutaryl curcumin (DGC) (Figure 1) , with greater lipophilic (DAC) and hydrophilic (DGC) properties respectively than curcumin. DAC has acetyl groups protecting the two polar phenolic groups of curcumin, making it more lipophilic (less polar) than curcumin. DGC has two free carboxylic groups on the side chain esters attached to the phenolic groups of curcumin making it considerably more hydrophilic (polar) than curcumin. In the current study we examined the in vivo anti-inflammatory and analgesic activities of curcumin, DAC and DGC, and compared them to aspirin. We also examined the in vitro inhibitory properties of these compounds on three cancer cell lines, breast cancer (SKBR-3), pancreatic cancer (PANC-1) and prostate cancer (PC-3) and compared them to the effect on a non-cancerous cell line, WI-38. The drug doses for the in vivo studies were decided based on the review of available literature and a pilot study in animals. Drugs were administered orally with food. flick reflex with a cut-off time of 5 seconds. For each animal, the tail flick latency was obtained thrice before drug administration and the mean was used as pre-drug latency. The tail flick latencies were measured at 0, 0.5, 1, 1.5, 2 and 3 h after administration of compounds (Table 2 ). For animals that did not respond within the cut-off time of 10 seconds, the value of the cut-off time was considered as the latency period for that animal [10] . Results were expressed as % maximum possible effect (MPE) [11] .
%MPE = (Post treatment latency-Pretreatment latency)x100 Pretreatment latency
Carrageenan induced rat paw edema: Increase in paw diameter was taken as an index of increase in paw volume, which is a measure of edema [9] . Measurements were taken immediately before and at 1, 2 and 3 hours after carrageenan injection. The inhibitory activity was calculated according to the following formula [10] (Ct-Co) control -(Ct-Co) treated x 100
Ct-Linear paw circumference after carrageenan injection (in our study, it was at 1, 2 and 3 hours after injection), Co-Linear paw circumference before carrageenan injection. In vivo studies: Table 1 gives the drug and the corresponding dose for the various groups used in the in vivo studies. Table 2 shows the effect of the drugs on tail flick latency in all groups. There was no statistically significant change in the tail flick latency in the control group (group 1). There was significant increase in latency with all curcumin formulations (p<0.05). The increase was maximal in group 4 at 180 minutes, followed by group 3 at 60 minutes. Aspirin 100 mg/kg (group 5) significantly increased latency time as compared with the control group (p<0.05) at 30 minutes.
In group 3 latency time peaked at 60 minutes, while in group 4 it peaked at 180 minutes. Latency time was significantly higher with all curcumin formulations compared with groups 1 and 5 (controls). The latency time was significantly higher at all time intervals in group 3 and 4 as compared with group 1. In group 2, latency time was significantly more only at 90 minutes. The latency time was significantly more in group 3 at 30, 60 and 90 minutes as compared with group 5, and significantly more in group 4 than group 3 at 30, 60 and 180 minutes. The MPE was more with all drugs when compared with group 1 (Figure 2 ). MPE was highest in group 4, followed by groups 2, 3 and 5. The MPE was significantly more in group 2 and 4 than group 5. The MPE was also significantly more in group 4 than group 3. 
Paw edema method:
There was significant increase in paw measurements (mm) after carrageen injection in the control group (Table 3 ). All chemicals inhibited the development of paw edema (Figure 3 ). Aspirin significantly inhibited the development at 1, 2 and 3 hours when compared with the control group (p<0.05). Group 4 inhibited paw edema significantly more than group 1 at 1 and 2 h. The effect of groups 2 and 3 was comparable to group 5 (control).
The inhibition was less in group 4. The percentage inhibition of edema was maximal in group 3, followed by groups 5, 2 and 4. The percentage inhibition was significantly more in group 3 than groups 2 (1 h) and 4. In vitro studies on cell lines: Anti-cancer cell culture assays were performed with three cancer cell lines, SKBR-3 (breast cancer), PANC-1 (pancreatic cancer) and PC-3 (prostate cancer), and a noncancerous lung fibroblast cell line, WI-38. The compounds were delivered to cells by extracellular perfusion in media. Five serial dilutions per compound were tested on a total of 4 cell lines in 96well plates. Cellular inhibition was measured using Alamar Blue. After addition of compound, 24 and 48 hour time points were taken, using a fluorescent plate reader. Data were analyzed to obtain % inhibition bar graphs, % inhibition line graphs and IC 50 growth inhibition values.
At 24 hours, DAC (Figure 4 ) inhibited PANC-1 and PC-3 at doses greater than 50 M. It inhibited SKBR-3 cancer lines at greater than 150 M doses. DGC at 24 hours ( Figure 5 ) behaved similarly, except that at the lower doses it more specifically inhibited the PANC-1 cell line. Both drugs at 24 hours had an insignificant effect on the non-cancerous, WI-38 cell line, even though curcumin had the lowest activity (Table 4 ). Both DAC and DGC had very similar activities, except at 24 hours for PANC-1, where the activity of DAC was relatively lower. At 24 hours DAC had a growth promoting effect on WI-38 at 300 M (Table 5) . At 48 hours, all three compounds had a very strong effect on the breast cancer cell line, SKBR-3 and on the prostate cancer cell line, PC-3. Curcumin had a relatively stronger effect on PC-3 than the two derivatives. Curcumin has two phenolic hydroxyl groups, acetylation of which makes curcumin less polar and more lipophilic. On the other hand, derivatization of the two phenolic groups with glutaryl groups gives five-carbon side chains with two free carboxylic acid groups, which makes the compound more water soluble than curcumin and the water solubility can be increased further by converting into sodium salts using sodium bicarbonate solution. The retention values (R f ) on thin layer chromatography (TLC) correspond to these polar characteristics of the two derivatives. The tail flick method demonstrates the analgesic activity of the compound. In our study, there was significant increase in tail flick latency with all formulations of curcumin; this was greater than the effect of aspirin, indicating higher efficacy. The results also depict the peak analgesic effect at 60 minutes and 180 minutes with curcumin diacetate and curcumin diglutarate, respectively. The latency time was even more with curcumin diglutarate than curcumin diacetate at 30 and 180 minutes. MPE was maximal with curcumin diglutarate, followed by curcumin diacetate, curcumin, and aspirin. This indicates a higher analgesic efficacy of curcumin diglutarate as compared with curcumin diacetate, curcumin and aspirin.
Carrageenan-induced hind paw edema is the standard experimental model of acute inflammation. Carrageenan is the agent of choice for testing anti-inflammatory drugs as it is not known to be antigenic and is devoid of apparent systemic effects. Moreover, the experimental model exhibits a high degree of reproducibility [12] . Carrageenan-induced edema is a biphasic response. The first phase is mediated through the release of histamine, serotonin and kinins, whereas the second phase is related to the release of prostaglandin and slow reacting substances, which peak at 3 hours [13] . In our study, the increase in the paw circumference following carrageenan administration in the vehicle control and aspirin treated group corresponds with previous findings [14, 15] . The curcumin formulations produced dose-dependent and significant inhibition of carrageenan-induced paw edema. The effect produced is equivalent to that of aspirin, indicating similar efficacy. The percentage inhibition corresponds with the paw circumference changes at all-time intervals. The percentage inhibition was maximum at 2 hours with aspirin and groups 2 and 3 (curcumin and DAC) depicting a similar action over time. Curcumin diglutarate (DGC) was less effective in this model than aspirin and the other two formulations, curcumin and DAC. The inhibitory effect on cancer cell growth is evident on all the three cancer cell lines with the two curcumin derivatives as well as with curcumin. Even though the two phenolic groups are protected for the derivatives, their activities were nearly as strong as that of curcumin at 24 and 48 hours after treatment with the curcumin analogs 1 and 2. The IC 50 values were slightly higher than that of curcumin; however, they were comparable with each other. The inhibition of non-cancerous cells (WI-38) was either low or negative for the two derivatives. DAC has an inhibitory effect on the cancer cells, especially between 4-24 hours. There is no inhibitory effect with the normal cell line at 24 and 48 hours; the normal cell line has the least inhibitory effect. For DGC, comparison of WI-38 (the non-cancerous cell line) with PC3 or SKBR3 showed a positive effect on the cancer lines, but not on the non-cancerous cell line. This is most noticeable with curcumin. The PC3 and WI-38 cell lines behaved similarly to DGC and curcumin. DAC and curcumin have a stronger effect on the fast dividing cancer cells as evident in the figure showing percent inhibition at various times. For cancer chemotherapy the ideal agent needs to have the selectivity to kill cancer cells with minimal toxicity to normal cells. Curcumin induces apoptosis at the G 2 phase of the cell cycle in deregulated cyclin D1-expressed mammary epithelial carcinoma cells, leaving its normal counterpart unaffected, and curcumin could thus be developed into an effective chemopreventive and chemotherapeutic agent [16, 17] .
In conclusion, the results of the present study indicate that curcumin diacetate has in vitro anti-cancer activities and significant anti-inflammatory activity comparable with aspirin, and curcumin diglutarate has significant analgesic activity higher than that of aspirin. Further in vivo studies are needed with various doses on disease models for analgesic and anti-inflammatory activity and anti-cancer activity studies using other cancer cell lines.
Experimental
General: Curcumin was obtained from turmeric powder by extraction with ethyl acetate after removal of turmeric oil using n-hexane extraction. The yellow solid containing curcumins, obtained by crystallization, was used without further purification.
Curcumin diacetate (2):
A mixture of curcumin (1.0 g), acetic anhydride (20 mL) and pyridine (2 mL) was heated in a round bottom flask at 80 o C for 2 h and left overnight with stirring at 60 o C. The mixture was cooled to room temperature and 50 mL ice cold water was added. The water layer was mixed with 100 mL NaHCO 3 solution (5%, w/v) and stirred for 0.5 h. The water layer was extracted with chloroform (20 mL x3). The combined extracts were washed first with 1N HCl (50 mL x 2), then brine (40 mL x 2), dried over anhydrous Na 2 SO 4 , concentrated in a rotovapor, and dried under high vacuum (0.5 torr) to obtain 1.1 g of yellow solid. 
Curcumin diglutarate (3):
Curcumin (1.0 g, 2.73 mmols) was added to 50 mL of anhydrous tetrahydrofuran (THF) in a 250 mL round bottom flask under a nitrogen atmosphere with stirring. Triethylamine (1.33 mL) and dimethylaminopyridine (56 mg) were added to the curcumin solution. The color changed from yellow to light red. A solution of glutaric anhydride (0.685 g, 6 mmols) in 5 mL of anhydrous THF was added dropwise to the mixture, which was stirred under reflux overnight under a nitrogen atmosphere. The mixture was cooled and concentrated in a rotovapor. The concentrate was dissolved in 50 mL ethyl acetate (EtOAc) and washed with ice cold 0.5N HCl solution (20 mL), followed by brine (20 mL). The combined aqueous wash was extracted with EtOAc (25 mL). The combined EtOAc extracts were dried over anhydrous Na 2 SO 4 , concentrated in a rotovapor and dried under high vacuum (0.5 torr) to obtain 1.30 g of yellow solid. Solubility in 5% sodium bicarbonate solution was ~2 mg/ mL. 
